Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the solid tumor testing market size evolved in recent years?

In recent times, there has been a robust increase in the market size of solid tumor testing. The market, which stood at $27.96 billion in 2024, is projected to rise to $30 billion in 2025, at a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the expansion during the historical period include the emergence of personalized or precision medicine, inefficient tumor-specific drug delivery, decreased therapeutic effectiveness, unrealistic costs, as well as simplistic approaches to cancer chemotherapy treatments.

What are the predictions for the solid tumor testing market size in the coming years?

The market size of solid tumor testing is projected to witness substantial expansion in the coming years, escalating to a value of $40.06 billion in 2029 with a CAGR of 7.5%. This predicted surge in the forecast period is linked to an increased incidence of cancer, a rise in healthcare infrastructure, the advent of diagnostic devices based on artificial intelligence and the Internet of Things, and expanding government initiatives. Key trends influencing this forecast period encompass the enhancement of diagnostic instruments, the launch of nanocarrier-based treatments, strategic alliances, and the advent of next-generation testing equipment.

Get your solid tumor testing market report here!

https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

What key factors are fueling the growth of the solid tumor testing market?

The solid tumor testing market’s growth is anticipated to be fueled by a rise in cancer prevalence. Cancer, a disease characterized by uncontrolled growth and proliferation of rogue cells in the body, can invade adjacent tissues and organs. In certain incidences, these cancer cells can even migrate to other body parts through the bloodstream or lymphatic system. Approximately 90% of cancers in adults are solid tumors. Solid tumor testing is a tool used to identify cancerous cells in the blood of patients suffering from solid tumors, even when the cancer is undetectable via imaging tests. An example is a report from the Centers for Disease Control and Prevention in June 2023, which notes that in the US in 2020, there were 1,603,844 fresh cancer cases and 602,347 cancer-related deaths, with 403 new cancer cases and 144 cancer-associated deaths for every 100,000 individuals. Consequently, the rising incidence of cancer is propelling the solid tumor testing market’s expansion.

How is the global solid tumor testing market divided into key segments?

The solid tumor testing market covered in this report is segmented –

1) By Type: Genetic Testing, Conventional Testing

2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

3) By Application: Clinical, Research

4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

Subsegments:

1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

Who are the key firms paving the way for growth in the solid tumor testing market?

Major companies operating in the solid tumor testing market include Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.

Which trends are expected to transform the solid tumor testing market?

A prominent trend emerging in the solid tumor testing market is the creation of innovative liquid biopsy test solutions. This trend is led by top companies in the market who are in a race to devise new liquid biopsy tests to consolidate their market positioning and achieve a competitive edge. For instance, NeoGenomics Inc., a testing laboratory company based in the US, unveiled a complete set of three liquid biopsy tests for cancer patients in June 2020. These ground-breaking tests are capable of identifying cancer cells in patients’ blood who have solid tumors, even before any signs of cancer are visible on imaging tests. These tests aid doctors in making informed decisions about the subsequent testing or treatment procedures. Apart from being non-invasive, these tests have the added benefits of early detection, potential for personalizing treatment and they are FDA-approved. These three tests have a turnaround time of a week or less, which can lead to significant time savings for clinicians.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12658

What regions are contributing significantly to the growth of the solid tumor testing market?

North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Solid State Relay Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/solid-state-relay-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Tumor Embolization Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: